Friday, Feb. 22, 2019
News Recap:
Time to Change Protocols for Post-SVR Monitoring for Liver Cancer?
In Memoriam: Anita York (May 27, 1953 - Feb. 7, 2019)
Funding via “Womens Wellness & Leadership Project” for women in BC living with HCV (&/or HIV)
MAVIRET™ 8 week, pan-genotypic HCV treatment, good for CKD & cirrhosis, covered in Ontario
No Time to Relax about Liver Cancer after HCV Treatment: Time to Change Monitoring
Finally, Maviret, AbbVie's hepatitis C drug, has made it through Canada's approval process and has been listed for coverage by Ontario's PharmaCare. We hope BC PharmaCare will also list it soon.
"MAVIRET™ is the first and only 8-week, pan-genotypic treatment for chronic hepatitis C patients without cirrhosis and who are new to treatment (from: Decisions Resources Group. Hepatitis C virus: disease landscape & forecast 2016 and 2017)...
MA...
Funding of up to $2500 is available to support women's self-directed health and education ideas...to improve health, wellness, skills building and social connectivity." More Information at...
https://www.vancouverfriendsforlife.ca/women-s-welleness-project
First deadline: March 15, 2019 (results announced March 30th)
Current protocols for HCV post-SVR monitoring may need updating to expand screening for liver cancer to those without cirrhosis. This article is dedicated to all non-cirrhotics who have been diagnosed with liver cancer following treatment for HCV.
HepCBC's volunteer Webmaster, CD Mazoff, PhD (discourse analysis, McGill), is battling liver cancer (HCC). For several years, CD has faithfully published the online HepCBC Weekly Bull every Friday, showcasing Ca
Anita York: May 27, 1953 - Feb. 7, 2019
Our beautiful friend, Anita York (May 27, 1953 - Feb. 7, 2019), was honoured Feb. 17, 2019 in a private family ceremony. HepCBC, for whom she worked for many years as a key volunteer and as a Coordinator of Volunteers, is mourning the loss of this outspoken peer advocate, always ready to battle for anyone fighting hepatitis C, or to prevent even one more person from suffering from this debilitating disease. A...
Friday, Jan 25, 2019
News Recap:
Using Telemedicine HCV Care Model in Prisons in SPAIN
“HCV telemedicine program satisfying, cost-effective in Spanish prison: A telemedicine program brought high levels of satisfaction and proved cost effective in patients with hepatitis C in a Spanish prison, according to data presented at The Liver Meeting 2018…” Read more about Spain’s prison-based HCV “Telemedicine” treatment model.
Saturday in Surrey! Visit HepC
“Nurse-led HCV care model results in 95% or higher SVR rates in prison: A decentralized, nurse-led model of hepatitis C care with direct-acting antivirals was significantly effective and led to high levels of sustained virologic response in a large cohort of inmates, according to a recently published study…” Read more...
https://www.healio.com/hepatology/hepatitis-c/news/online/%7B33a10536-2c18-4632-9f19-995fafe9dd16%7D/nurse-led-hcv-care-model-results-in
“HCV telemedicine program satisfying, cost-effective in Spanish prison: A telemedicine program brought high levels of satisfaction and proved cost effective in patients with hepatitis C in a Spanish prison, according to data presented at The Liver Meeting 2018…” Read more...
https://www.healio.com/hepatology/hepatitis-c/news/online/%7b83ec8dfd-e12f-4288-9883-01a696c97dfa%7d/hcv-telemedicine-program-satisfying-cost-effective-in-spanish-prison...
Come visit HepCBC’s “Liver Wellness” info table at the Surrey Health Expo on Saturday, January 26, 2019 between noon and 5 pm. It is at Surrey City Hall, 13450 – 104 Avenue in Surrey. Please stop by to say hello to our volunteers Dr. Anuradha Dhavan, Dr. Urvashi Beruar, and peer advocate Cheryl Reitz. View poster at: http://hepcbc.ca/wp-content/uploads/2019/01/20190126_SurreyHealthExpo.pdf
View Hep CBC’s 2 page spread in South Asian Health magazine! The
HepCBC is quite interested in NASH because people with hepatitis C are particularly vulnerable to NASH, even after being cured of hepatitis C! (Reference for relation between post-SVR HCV and NASH: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859229/)
Register for free CCO webinar: “Identifying and Managing NASH [Non-alcoholic steatohepatitis] in High-Risk Populations: A Silent Epidemic, NASH affects 30 million Americans, or 12% of all adults. By 202
